The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: A cost-effectiveness analysis

被引:22
作者
Comay, Dan [1 ]
Adam, Viviane [2 ]
da Silveira, Eduardo B. [1 ]
Kennedy, Wendy [3 ]
Mayrand, Serge
Barkun, Alan N. [1 ,2 ]
机构
[1] McGill Univ, Div Gastroenterol, Montreal, PQ H3A 2T5, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ H3A 2T5, Canada
[3] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
关键词
GERD; proton pump inhibitors; Stretta procedure;
D O I
10.1155/2008/765458
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: The Stretta procedure is an endoscopic therapy for gastroesophageal reflux disease. OBJECTIVE: To evaluate the cost-effectiveness of the Stretta procedure and that of competing strategies in the long-term management of gastroesophageal. reflux disease. METHODS: A Markov model was designed to estimate costs and health outcomes in Canadian patients with gastroesophageal reflux disease over five years, from a Ministry of Health perspective. Strategies included the use of daily proton pump inhibitors (PPIs), laparoscopic Nissen fundoplication (LNF) and the Stretta procedure. Probabilities and utilities were derived from the literature. Costs are expressed in 2006 Canadian dollars. Units of effectiveness were symptom-free months (SFMs) and quality-adjusted life years (QALYs), using a five-year time horizon. RESULTS: In the analysis that used SFMs, the strategy using PPIs exhibited the lowest costs ($40 per SFM) and the greatest number of SFMs, thus dominating both the LNF and Stretta systems. But the cost-effectiveness analysis using QALYs as the measure of effectiveness showed that PPIs presented the lowest cost-effectiveness ratio, while both the LNF and Stretta strategies were associated with very high incremental costs (approximately $353,000 and $393,000, respectively) to achieve an additional QALY. However, the PPI strategy did not dominate the two other strategies, which were associated with better effectiveness. CONCLUSIONS: If SFMs are used as the measure of effectiveness, PPIs dominate the Stretta and LNF strategies. However, if QALYs are used, the PPIs still present the lowest cost and LNF gives the best effectiveness. Regardless of the units of effectiveness or utility used in the present cost analysis, an approach of prescribing PPIs appears to be the preferred strategy.
引用
收藏
页码:552 / 558
页数:7
相关论文
共 47 条
[1]   Preoperative symptom evaluation and esophageal acid infusion predict response to laparoscopic Nissen fundoplication in gastroesophageal reflux patients who present with cough [J].
Allen, CJ ;
Anvari, M .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2002, 16 (07) :1037-1041
[2]  
ARMSTRONG D, 2003, CAN J GASTROENTEROL, V17, pA105
[3]   The Canadian Registry on nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting [J].
Barkun, A ;
Sabbah, S ;
Enns, R ;
Armstrong, D ;
Gregor, J ;
Fedorak, RN ;
Rahme, E ;
Toubouti, Y ;
Martel, M ;
Chiba, N ;
Fallone, CA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (07) :1238-1246
[4]   High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis [J].
Barkun, AN ;
Herba, K ;
Adam, V ;
Kennedy, W ;
Fallone, CA ;
Bardou, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (05) :591-600
[5]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[6]   An introduction to Markov modelling for economic evaluation [J].
Briggs, A ;
Sculpher, M .
PHARMACOECONOMICS, 1998, 13 (04) :397-409
[7]   Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease [J].
Briggs, AH ;
Goeree, R ;
Blackhouse, G ;
O'Brien, BJ .
MEDICAL DECISION MAKING, 2002, 22 (04) :290-308
[8]  
Canadian Co-ordinating Office for Health Technology Assessment , 1997, GUID EC EV PHARM CAN
[9]   Evidence-based appraisal of antireflux fundoplication [J].
Catarci, M ;
Gentileschi, P ;
Papi, C ;
Carrara, A ;
Marrese, R ;
Gaspari, AL ;
Grassi, GB .
ANNALS OF SURGERY, 2004, 239 (03) :325-337
[10]   Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review [J].
Contini, S ;
Scarpignato, C .
DIGESTIVE AND LIVER DISEASE, 2003, 35 (11) :818-838